September 4, 2013 | ImClone's Sam Waksal is making biotech plans again. Hoping to cash in on biotech's current success, Waksal is planning to spin out two units of his Kadmon Corp that focus on gene therapy and metabolomics and start a Chinese subsidiary. Bloomberg